Answers are grounded in this paper and cite their sources.
In type 1 diabetes (T1D), insulin-producing β cells are destroyed by an autoimmune response driven by pro-inflammatory cytokines. The signaling of these cytokines is partially mediated by post-translational modifications, such as phosphorylation and acetylation. However, the role of other post-translational modifications in β-cell cytokine signaling represents an important knowledge gap. In the context of autoimmune diseases, lysine carbamylation has gained attention for its role in pathogenesis. Here, we investigate possible roles of carbamylation in T1D. We found that pancreata from the T1D model, non-obese diabetic (NOD) mice, at pre-diabetic stage (8-9 weeks old) exhibit 11% carbamylation-positive β cells, whereas non-diabetic CD1 mice have only 5%. Proteomics analysis of the MIN6 insulin-producing cell line treated with a cocktail of three pro-inflammatory cytokines IFNγ + IL-1β + TNFα identified 284 carbamylated peptides from 222 proteins regulated by the cytokine treatment. Integration of carbamylation and acetylation provided a deep view of the cytokine-regulated PTMs and potential points of interplay. A functional-enrichment analysis revealed that carbamylation was enriched in pathways related to autoimmune diseases, metabolism, DNA replication, and protein translation. Moreover, functional testing demonstrated that carbamylation inhibits the glycolytic enzyme aldolase A and the insulin-processing enzyme carboxypeptidase E, identifying a possible role for cytokine-induced β-cell dysfunction. In summary, NOD mice have more carbamylated β cells than CD1 mice, and pro-inflammatory cytokine treatment regulates protein carbamylation in MIN6 cells. These data identified carbamylation as a potential regulatory mechanism for β-cell metabolism and insulin production in insulitis.
No takes yet. Share an insight, caveat, or question.
You et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: